HC Wainwright & Co. Downgrades Iterum Therapeutics to Neutral

Benzinga Newsdesk www.benzinga.com Negative 92.8%

Neg 92.8% Neu 0% Pos 0%

HC Wainwright & Co. analyst Matthew Keller downgrades Iterum Therapeutics (NASDAQ:ITRM) from Buy to Neutral.

Comments

No comments yet. Be the first!

HC Wainwright &amp; Co. Downgrades Iterum Therapeutics to Neutral